Could a targeted drug boost transplant success in tough blood cancers?

This early-phase study tests whether adding the drug venetoclax to standard transplant preparation and post-transplant maintenance can safely help prevent cancer return in people with high-risk acute myeloid leukemia, myelodysplastic syndromes, or related blood cancers. About 102 adults will receive venetoclax alongside chemotherapy before transplant, then continue it with another drug afterward. The main goal is to find safe doses, not yet to prove the approach works.